SVA - Sinovac Biotech Ltd.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
6.47
0.00 (0.00%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close6.47
Open6.49
Bid0.00 x 800
Ask0.00 x 1100
Day's Range6.25 - 6.58
52 Week Range5.73 - 7.43
Volume8,227
Avg. Volume0
Market Cap460.249M
Beta (3Y Monthly)0.22
PE Ratio (TTM)33.52
EPS (TTM)0.19
Earnings DateAug 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Here is What Hedge Funds Think About Sinovac Biotech Ltd. (SVA)
    Insider Monkey

    Here is What Hedge Funds Think About Sinovac Biotech Ltd. (SVA)

    The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

  • Business Wire

    Sinovac Reports Unaudited Third Quarter 2019 Financial Results

    Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third quarter ended September 30, 2019.

  • Business Wire

    Sinovac Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F

    Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in China, has filed its 2018 annual report on Form 20-F with the U.S.

  • Business Wire

    Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease

    The Sinovac-developed sIPV demonstrates both long-term affordability and accessibility and has the potential to contribute significantly to polio eradication in developing countries and the progress towards a polio-free world. Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the positive results from the Company’s Phase III clinical study of a Sabin strain-based inactivated polio vaccine (sIPV) developed by Sinovac were published in the Journal of Infectious Disease.

  • Business Wire

    Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares

    Sinovac Biotech Ltd. (SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update for shareholders with regards to the exchange (the “Exchange”) of preferred share purchase rights (the “Rights”) for the Company’s Common Shares and Series B Convertible Preferred Shares (the “Exchange Shares”), originally announced on February 22, 2019, by press release. On April 4, 2019, the Eastern Caribbean Supreme Court, Court of Appeal issued an order that restrains the Company from taking further action under its Rights Agreement, including the distribution of the previously issued Exchange Shares to the holders of valid Rights, until the conclusion of 1Globe Capital, LLC’s appeal of the December 19, 2018 Judgment of the High Court of Justice of Antigua and Barbuda.

  • Business Wire

    Sinovac Determines Trigger Event Occurred Under Rights Agreement

    Board of Directors Amends and Restates Rights Agreement and Declares Dividend Distribution of New Preferred Share Purchase Rights. Sinovac Biotech Ltd. (SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its Board of Directors (the “Board”) determined that certain stockholders became “Acquiring Persons,” as defined in the Company’s Rights Agreement (“Rights Agreement”), prior to the Company’s Annual General Meeting held on February 6, 2018 (the “AGM”).

  • Reuters

    Sinovac Biotech activates 'poison pill' defense in rare move

    Sinovac Biotech Ltd, a Nasdaq-listed Chinese vaccine developer, activated a shareholders rights plan on Friday, according to a press release seen by Reuters, the first time a company has used a "poison pill" takeover defense in more than a decade. Sinovac is seeking to defend itself against a group of shareholders, including investment firms 1Globe Capital LLC, Chiangjia Li and OrbiMed Advisors LLC, which own 40 percent of the company. While companies occasionally threaten to use poison pill defenses, they rarely proceed.

  • GlobeNewswire

    Nasdaq Halts Sinovac Biotech Ltd.

    NEW YORK, Feb. 22, 2019 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted today in Sinovac Biotech Ltd. (Nasdaq: SVA) at 16:02:01 p.m. Eastern Time.

  • Can Sinovac Biotech Ltd.’s (NASDAQ:SVA) ROE Continue To Surpass The Industry Average?
    Simply Wall St.

    Can Sinovac Biotech Ltd.’s (NASDAQ:SVA) ROE Continue To Surpass The Industry Average?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...